See Figure 1, these proteins have been shown to be clinically effective against cancers with the deficient DNA repair due to the germline mutations in the BRCA1 and BRCA2, which is estimated to account for 5% to 7% of pancreatic cancer patients. This evidence concerns the gene BRCA2 and pancreatic neoplasm.